Serplulimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: First-line advanced squamous NSCLC with carboplatin and nab-paclitaxel (article dated... (EU)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Small Cell Lung Cancer · Phase 3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US

Also approved (7)
EU
  • First-line advanced squamous NSCLC with carboplatin and nab-paclitaxel (article dated 2026-06-25)allsci.com
  • First-line non-squamous NSCLC (no EGFR or ALK/ROS1 mutations) with carboplatin and pemetrexed; also metastatic oesophageal squamous cell carcinomaallsci.com
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposide (Hetronifly)persportaal.anp.nl
Product first approved 2025
CH
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposide (Hetronifly)
Product first approved 2025swissmedic.ch
UK
  • Adults with previously untreated extensive-stage small cell lung cancer (Hetronifly)
Product first approved 2025persportaal.anp.nl
CN
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposidefosunpharma.com
  • First-line unresectable locally advanced or metastatic squamous NSCLC with carboplatin and nab-paclitaxelfosunpharma.com
Product first approved 2022

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (18)
Gastric Cancer
NCT04139135 · Shanghai Henlius Biotech
2019-12-12 – 2024-10 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
NCT07739758 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-08-18 – 2030-04 · SCLC, Extensive Stage
What this study did
NCT05353257 · Shanghai Henlius Biotech
2022-05-17 – 2028-05-30 · Limited-Stage Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07177443 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-09-26 – 2035-12-31 · Locally Advanced Nasopharyngeal Carcinoma
What this study did
NCT07904156 · Sun Yat-sen University
2026-10-21 – 2032-12-30 · Non-Clear Cell Renal Cell Carcinoma (nccRCC)
What this study did
NCT07877597 · Fudan University
2026-10-15 – 2031-12-31 · Locally Advanced Colon Cancer, pMMR
What this study did
NCT07235930 · Zhejiang Cancer Hospital
2025-11-15 – 2029-07-01 · Non-Resectable Pancreas Carcinoma
What this study did
NCT07113275 · Tao Zhang
2026-05-15 – 2028-12-31 · Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, Immunotherapy
What this study did
NCT07277842 · Sun Yat-sen University
2025-12-29 – 2028-12-29 · Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
What this study did
NCT07336953 · West China Hospital
2026-02 – 2028-07 · PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT07020247 · West China Hospital
2024-11-19 – 2028-01-31 · Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy, Anal Function Preservation
What this study did
NCT04806945 · Shanghai Henlius Biotech
2022-09-30 – 2024-10-30 · Cervical Cancer
What this study did
NCT04465734 · Shanghai Henlius Biotech
2022-11-15 – 2024-03-15 · Hepatocellular Carcinoma (HCC)
What this study did
NCT03958890 · Shanghai Henlius Biotech
2019-06-19 – 2023-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
Phase 2/3 (5)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06280495 · Sun Yat-sen University
2024-02-01 – 2029-12-31 · Colorectal Cancer, Liver Metastases
What this study did
NCT07134218 · Changhai Hospital
2025-10 – 2027-10 · Rectal Cancer
What this study did
NCT04547166 · Shanghai Henlius Biotech
2021-03-10 – 2026-12-30 · Metastatic Colorectal Cancer
What this study did
Phase 2 (113)
Gastric Cancer
NCT07257575 · Guangdong Provincial People's Hospital
2025-01-05 – 2031-06-30 · Gastric Cancer Stage III
What this study did
NCT07507916 · Fudan University
2026-04-01 – 2029-12-31 · ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment
What this study did
NCT07943533 · Shanghai Zhongshan Hospital
2026-12-01 – 2029-12-31 · HER2-Positive, Limited Metastatic, Gastric Cancer
What this study did
NCT07938021 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-12-01 – 2029-12-01 · Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC)
What this study did
NCT07872696 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-09 – 2029-09 · Gastric Neoplasms
What this study did
NCT05975749 · Fudan University
2023-01-01 – 2029-01-01 · Gastric Cancer
What this study did
NCT07933471 · Beijing Tsinghua Chang Gung Hospital
2026-08-05 – 2028-12-30 · Gastric Cancer (GC), Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
NCT07621484 · Shanghai Changzheng Hospital
2026-07-13 – 2028-05-09 · Locally Advanced Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07391826 · The First Affiliated Hospital with Nanjing Medical University
2026-02-15 – 2027-12-31 · Stage III Gastric Cancer
What this study did
NCT05311189 · Shanghai Zhongshan Hospital
2022-07-23 – 2027-12-31 · HER2-positive Gastric Cancer
What this study did
NCT06461910 · Zekuan Xu
2024-06-14 – 2027-12 · Gastric Cancer, Esophagogastric Junction Adenocarcinoma
What this study did
NCT06531291 · RenJi Hospital
2024-08-10 – 2027-08-09 · ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer
What this study did
NCT06439550 · The First Affiliated Hospital of Zhengzhou University
2024-07-15 – 2026-12-31 · HER2-positive Gastric Cancer
What this study did
NCT06576921 · Xijing Hospital
2024-11-15 – 2026-12-30 · Stomach Neoplasms, Immune Checkpoint Inhibitors
What this study did
NCT05585580 · Qilu Hospital of Shandong University
2023-03-01 – 2026-11-01 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05769725 · RenJi Hospital
2023-03-01 – 2026-03-31 · Serplulimab,Gastric Cancer, Adjuvant Therapy
What this study did
NCT05942573 · Tianjin Medical University Cancer Institute and Hospital
2022-12-24 – 2024-12-31 · Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
NCT05246982 · Shanghai Henlius Biotech
2022-03-23 – 2024-03-30 · Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
What this study did
Non-Small Cell Lung Cancer
NCT05882513 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-05-16 – 2030-12-31 · NSCLC, Neoadjuvant Therapy
What this study did
NCT07398937 · Fudan University
2026-02-05 – 2029-12-31 · Resectable Stage II-IIIa Squamous NSCLC
What this study did
NCT07253142 · Shanghai Henlius Biotech
2026-02-05 – 2028-06-19 · Non Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
NCT07064876 · Xi Junjie
2025-10 – 2027-09 · Early Lung Cancer
What this study did
NCT07596121 · Tang-Du Hospital
2026-05-13 – 2027-05-31 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT05957510 · Guangdong Association of Clinical Trials
2023-07-07 – 2026-12-31 · Small-cell Lung Cancer
What this study did
NCT05837052 · Zhejiang University
2023-05-15 – 2026-12-30 · Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT07269782 · Shanghai Henlius Biotech
2026-01-20 – 2026-11-30 · Non Small Cell Lung Cancer
What this study did
NCT05775796 · Fudan University
2023-03-15 – 2025-09-01 · Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy, Neoadjuvant Therapy
What this study did
NCT06334757 · Henan Cancer Hospital
2023-05-08 – 2025-06-30 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT06195683 · Zhejiang Cancer Hospital
2023-12-01 – 2025-06-20 · Non-small Cell Lung Cancer, PDL1 Gene Mutation
What this study did
NCT04976647 · Shanghai Henlius Biotech
2022-01-18 – 2024-10-30 · Squamous Non-small-cell Lung Cancer
What this study did
NCT05675033 · Fujian Cancer Hospital
2023-01-10 – 2024-01-10 · Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor, VEGF
What this study did
Small Cell Lung Cancer
NCT06295926 · Peking Union Medical College Hospital
2024-04-04 – 2027-12-31 · Small Cell Lung Cancer
What this study did
NCT05468489 · Shanghai Henlius Biotech
2022-11-18 – 2027-12-31 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT07583511 · Sun Yat-sen University
2024-02-01 – 2027-12-01 · Small-cell Lung Cancer
What this study did
NCT06812260 · Shanghai Henlius Biotech
2025-06-24 – 2027-10-31 · SCLC, Extensive Stage
What this study did
NCT06554535 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2024-10-01 – 2027-10-01 · Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer, ECOG Performance Status Score of 0 or 1, Expected Survival ≥3 Months
What this study did
NCT05765825 · Sichuan University
2023-03-07 – 2026-12-31 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT06497530 · Guangzhou Institute of Respiratory Disease
2024-12-01 – 2026-12 · Extensive-Stage Small Cell Lung Cancer
What this study did
NCT06911606 · Guangdong Provincial People's Hospital
2024-05-22 – 2026-06-30 · SCLC, Limited Stage
What this study did
NCT05443646 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-09-23 – 2025-06-30 · Limited Stage Small Cell Lung Cancer
What this study did
NCT05354700 · Shanghai Henlius Biotech
2023-03-29 – 2024-05-29 · Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT07713745 · Beijing Tiantan Hospital
2026-07-18 – 2036-12-31 · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2
What this study did
NCT06850103 · First Affiliated Hospital of Zhejiang University
2025-04-22 – 2032-12 · Colorectal Carcinoma, Oligometastases, pMMR, MSS, iTNT
What this study did
NCT07772557 · The First Affiliated Hospital with Nanjing Medical University
2026-09-01 – 2032-01-20 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07381400 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2026-02-01 – 2031-12-31 · Rectal Cancer
What this study did
NCT07283692 · RenJi Hospital
2026-03-01 – 2031-09 · Triple Negative Breast Cancer
What this study did
NCT07527520 · Fudan University
2026-06 – 2031-06 · Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS
What this study did
NCT07466303 · Xijing Hospital
2026-03-25 – 2031-04-01 · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
What this study did
NCT07347951 · First Affiliated Hospital of Wenzhou Medical University
2025-12-01 – 2030-12-01 · Locally Advanced Rectal Cancer (LARC)
What this study did
Phase 1/2 (8)
Non-Small Cell Lung Cancer
NCT06848699 · Shanghai Henlius Biotech
2025-02-25 – 2027-10-01 · Solid Tumor Cancer, Non Small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07141771 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2030-12-31 · SCLC, Extensive Stage
What this study did
NCT05882630 · Fujian Cancer Hospital
2023-06-01 – 2026-06-01 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07708285 · Beijing Tiantan Hospital
2026-07-31 – 2029-12-31 · NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, Meningioma
What this study did
NCT07175389 · West China Hospital
2026-09-01 – 2028-12-01 · Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
What this study did
NCT07358585 · Shanghai Henlius Biotech
2026-01-31 – 2028-08-23 · Colon Cancer Adenocarcinoma
What this study did
NCT05747729 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-06-21 – 2027-07-28 · Neuroendocrine Carcinoma
What this study did
NCT05501340 · Second Affiliated Hospital of Soochow University
2022-09-01 – 2024-09-01 · Malignant Ascites
What this study did
Phase 1 (9)
Small Cell Lung Cancer
NCT07231445 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-04-21 – 2028-12 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06716619 · Guangzhou FineImmune Biotechnology Co., LTD.
2025-02-13 – 2027-12-19 · Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
What this study did
NCT06115642 · Shanghai Henlius Biotech
2023-11-24 – 2027-11-30 · Advanced/Metastatic Malignant Solid Tumors
What this study did
NCT06302062 · Guangzhou FineImmune Biotechnology Co., LTD.
2023-06-06 – 2026-06-30 · Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
What this study did
NCT05483530 · Shanghai Henlius Biotech
2022-12-14 – 2025-08 · Advanced or Metastatic Solid Tumors
What this study did
NCT05400265 · Shanghai Henlius Biotech
2022-07-26 – 2024-01-31 · Adult Solid Tumor
What this study did
NCT03468751 · Henlix, Inc
2018-02-14 – 2020-08-31 · Solid Tumor
What this study did
Phase 4 (2)
Other / comorbidity
NCT06388135 · Yang Jianjun, PhD
2024-05-01 – 2027-05 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07446465 · Ye Xu
2026-03-01 – 2027-01-31 · Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
What this study did
Early phase / not applicable (6)
Gastric Cancer
NCT06128252 · Tang-Du Hospital
2024-09-01 – 2027-06-30 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06580665 · Shanghai Chest Hospital
2024-09-01 – 2030-08-11 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06462105 · Zhou Chengzhi
2024-07-05 – 2027-06-30 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07854964 · Tang-Du Hospital
2026-10-15 – 2031-05-15 · Locally Advanced Rectal Cancer
What this study did
NCT06156332 · Shanghai Changzheng Hospital
2024-01-28 – 2027-01-28 · Advanced Solid Tumors With Neuroendocrine Differentiation
What this study did
NCT06335147 · Henan Cancer Hospital
2024-04-01 – 2026-01-31 · Metastatic Colon Cancer
What this study did
Appears in other studies (11)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (9)
Gastric Cancer
NCT07784413 · Zhejiang Cancer Hospital
2026-09-01 – 2029-07-30 · Gastric Cancer Peritoneal Metastasis (GCPM)
What this study did
Non-Small Cell Lung Cancer
NCT07418866 · Fudan University
2026-02 – 2028-12 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT05766800 · Shanghai Pulmonary Hospital, Shanghai, China
2023-03-14 – 2027-04-01 · Locally Advanced, Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
Other / comorbidity
NCT07870798 · The First Affiliated Hospital with Nanjing Medical University
2026-10-15 – 2028-12-31 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06350162 · Zhejiang Cancer Hospital
2023-10-18 – 2025-12-31 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT04297995 · Shanghai Henlius Biotech
2020-07-29 – 2025-06-30 · Head and Neck Squamous Cell Carcinoma
What this study did
Early phase / not applicable (2)
Small Cell Lung Cancer
NCT06364046 · The Central Hospital of Lishui City
2024-04-01 – 2025-12-31 · Carcinoma, Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07674342 · Tongji Hospital
2026-06-30 – 2031-06-30 · Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Serplulimab: this drugPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Obrixtamig
Phase 3(overall)
Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
AL8326Phase 2Small moleculeAurora B / FGFR / VEGFR (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 103 furthest-along competitors are listed; 510 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Serplulimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (11)
December 2026 (11)
Phase 2Triple Negative Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT07283692 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT06497530 · CT.gov ↗
What to watch
Phase 1Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab InjectionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-19 · NCT06716619 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-28 · NCT05954429 · CT.gov ↗
What to watch
Phase 1Advanced/Metastatic Malignant Solid TumorsEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT06115642 · CT.gov ↗
What to watch
Phase 2pMMR, MSS, MSI-L, Locally Advanced Rectal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-30 · NCT05731726 · CT.gov ↗
What to watch
Phase 2Malignant AscitesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06433869 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06439550 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07391826 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05311189 · CT.gov ↗
What to watch
Phase 2/3Colorectal Cancer, Liver MetastasesRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT06280495 · CT.gov ↗
What to watch
2027 (39)
January 2027 (3)
Phase 2Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-25 · NCT06295926 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT07257575 · CT.gov ↗
What to watch
Phase 4Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-31 · NCT07446465 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT06601309 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Locally Advanced Pancreatic Ductal AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-15 · NCT07101679 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-01 · NCT07583511 · CT.gov ↗
What to watch
Phase 2Breast Cancer (Triple Negative Breast Cancer (TNBC))Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-15 · NCT07487519 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-31 · NCT07403435 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-18 · NCT07253142 · CT.gov ↗
What to watch
Phase 2Resectable Esophageal Squamous Cell CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07457528 · CT.gov ↗
What to watch
Early phase / not applicableSmall Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06462105 · CT.gov ↗
What to watch
Early phase / not applicableGastric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT06128252 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Urothelial Carcinoma, Biliary Tract Cancer, HER2RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT07506057 · CT.gov ↗
What to watch
Phase 3PDAC - Pancreatic Ductal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07 · NCT07336953 · CT.gov ↗
What to watch
Phase 1/2Colon Cancer AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-28 · NCT07358585 · CT.gov ↗
What to watch
Phase 3Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy, Anal Function PreservationRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-31 · NCT07020247 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-01 · NCT07733050 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-09 · NCT06531291 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer, Neoadjuvant TherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-08-31 · NCT07150949 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT07872696 · CT.gov ↗
What to watch
Phase 2Small-Cell Carcinoma of the EsophagealNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07155122 · CT.gov ↗
What to watch
Phase 2Locally Advanced Colorectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-01 · NCT07819604 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, RelapseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-10 · NCT07604909 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2/3Rectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10 · NCT07134218 · CT.gov ↗
What to watch
Phase 2Rectal Cancer Patients, Locally Advanced Rectal Cancer (LARC)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-01 · NCT07898865 · CT.gov ↗
What to watch
Phase 2Non-clear Cell Renal Cell CarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-22 · NCT05831891 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Cervical CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-30 · NCT07340489 · CT.gov ↗
What to watch
December 2027 (12)
Phase 2Locally Advanced Rectal Cancer (LARC)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-01 · NCT07347951 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal Cancer (CRC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-15 · NCT07622550 · CT.gov ↗
What to watch
Phase 2Carcinoma of Head and/or NeckRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT06857279 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT07933471 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07398937 · CT.gov ↗
What to watch
Phase 2Colorectal Carcinoma, Oligometastases, pMMR, MSS, iTNTRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT06850103 · CT.gov ↗
What to watch
Phase 2Non-Clear Cell Renal Cell CarcinomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07488533 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed MYC/BCL2 Double-expressor DLBCLActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07538180 · CT.gov ↗
What to watch
Phase 2Locally Advanced Colorectal Cancer, Colorectal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07691632 · CT.gov ↗
What to watch
Phase 2Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal MetastasisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07902648 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07943533 · CT.gov ↗
What to watch
2028 (18)
January 2028 (2)
Phase 3Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, ImmunotherapyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-01 · NCT07113275 · CT.gov ↗
What to watch
Phase 2Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low ExpressionNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-09 · NCT07446049 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Rectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07381400 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-typeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT05742425 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-01 · NCT07938021 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Breast CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT06860529 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Gastric CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-05-09 · NCT07621484 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSSNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07 · NCT07527520 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Colorectal Cancer (Diagnosis)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-31 · NCT07134101 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07175389 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT06580665 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT07699939 · CT.gov ↗
What to watch
December 2028 (5)
Phase 1Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07231445 · CT.gov ↗
What to watch
Phase 3Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-29 · NCT07277842 · CT.gov ↗
What to watch
Phase 1/2NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma, MeningiomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07708285 · CT.gov ↗
What to watch
Phase 2Rectal Neoplasms, Rectal AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07543848 · CT.gov ↗
What to watch
Phase 2pMMR/MSS, Locally Advanced Rectal Carcinoma, Fasting, IntermittentNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07779694 · CT.gov ↗
What to watch
2029 (5)
May 2029 (1)
Phase 2Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-05 · NCT07854977 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Small Cell Lung CancerRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06 · NCT07739758 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Non-Resectable Pancreas CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-01 · NCT07235930 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Gastric CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT07507916 · CT.gov ↗
What to watch
Phase 3Locally Advanced Colon Cancer, pMMRNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12-31 · NCT07877597 · CT.gov ↗
What to watch
2030 (3)
May 2030 (1)
Early phase / not applicableLocally Advanced Rectal CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-05-15 · NCT07854964 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1/2Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-30 · NCT07141771 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Non-Clear Cell Renal Cell Carcinoma (nccRCC)Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-12-30 · NCT07904156 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
Phase 2/3Non-Small Cell Lung CancerNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-12-31 · NCT07772557 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 3Locally Advanced Nasopharyngeal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2035-12-31 · NCT07177443 · CT.gov ↗
What to watch
2036 (1)
June 2036 (1)
Phase 2Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma, NF2-related Schwannomatosis, NF2Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2036-06-01 · NCT07713745 · CT.gov ↗
What to watch

See the full readout calendar ↗